A Single-arm Exploratory Study of Neoadjuvant Therapy

Inclusion Criteria: 1. Volunteer to participate in clinical research;Fully understand and be Informed of the study and sign the Informed Consent Form (ICF);Willing to follow and able to complete all test procedures; 2. Age 18-75 (boundary value included), no gender limitation; 3. Histologically proven stage II-IIIB Lung Adenocarcinoma (as defined by the American Joint Commission on Cancer, 8th Edition); 4. EGFR gene mutation positive (can be tested by tissue or blood samples); 5. PD-L1 ≥ 1% 6. ECOG PS score 0-1 (including boundary value); 7. Cardiopulmonary function is good, and the requirements for surgical resection for radical treatment are confirmed; 8. Meet the conditions for receiving platinum containing two-drug chemotherapy; 9. The expected survival time is ≥3 months, and feasible surgery is planned; Exclusion Criteria: 1. Any previous treatment for current lung cancer, including systemic therapy or radiotherapy; 2. there are locally advanced unresectable diseases (regardless of disease stage) and metastatic diseases (stage IV). 3. A history of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc.Patients with any severe and/or uncontrolled disease or symptom